Active Recombinant Human FCGR3A Protein, His-tagged

Specification :
| Source : HEK293 | Species : Human | Tag : His | Predicted N Terminal : Gly 17 | Form : Lyophilized from sterile PBS, pH7.4, 10% Trehalose. | Bio-activity : Measured by its binding ability in a functional ELISA. Immobilized Yervoy Ipilimumab (Human IgG1) at 5 μg/mL (100 μL/well) can bind Human FCGR3A / CD16a (V158), His Tag with a linear range of 1-16 ng/mL. The bioactivity is measured by its binding ability to Ipilimumab in a SPR assay. Immobilized Human FCGR3A / CD16a (V158), His Tag can bind Ipilimumab with affinity constant of around 171 nM. | Molecular Mass : Human FCGR3A / CD16a (V158), His Tag is fused with a polyhistidine tag at the C-terminus, and has a calculated MW of 23.7 kDa. The reducing protein migrates as 40-50 kDa in SDS-PAGE due to glycosylation. | Endotoxin : Less than 1.0 EU per μg by the LAL method. | Purity : >95% as determined by reduced SDS-PAGE. | Stability : Samples are stable for up to twelve months from date of receipt at -70ºC. | Storage : Store it under sterile conditions at -20ºC~-70ºC. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles. | Reconstitution : It is recommended that sterile water be added to the vial to prepare a stock solution of 0.2 ug/ul. Centrifuge the vial at 4℃ before opening to recover the entire contents.